Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to active thiol metabolite with inconsistent results....
Main Authors: | Damrus Tresukosol, Bhoom Suktitipat, Saowalak Hunnangkul, Ruttakarn Kamkaew, Saiphon Poldee, Boonrat Tassaneetrithep, Atip Likidlilid |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4199712?pdf=render |
Similar Items
-
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
by: Li L, et al.
Published: (2012-02-01) -
The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention
by: Zhaowei Zhang, et al.
Published: (2020-01-01) -
The polymorphism of cytochrome P450 CYP2C19 and resistance to clopidogrel.
by: C. Simoglou
Published: (2017-03-01) -
ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL
by: K. Yu. Lukianets, et al.
Published: (2020-10-01) -
The Pharmacogenetics of Cytochrome P450 2C19 Enzymes - Effects on Clopidogrel and Proton Pump Inhibitors
by: Yusmiati Yusmiati, et al.
Published: (2014-04-01)